Correlation Between Cardiac Markers and Severity of COVID-19

Correlation Between Cardiac Markers and Severity of COVID-19 in Egyptian Population

By July 9, 2020, the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had resulted in over 11.8 million confirmed cases and over 545000 deaths. Patients with a history of cardiovascular disease are especially vulnerable and have a bad prognosis. According to the findings, cardiac injury manifested by cardiac biomarker elevation is detected in a significant number of COVID-19 patients and is linked to poor outcomes and mortality. However, it is unclear how effective cardiac biomarkers are in COVID-19 prognosis and how to use these indicators.

Study Overview

• Status: Completed
• Conditions: Cardiac Event
• Intervention / Treatment: Other: laboratory investigation

Detailed Description

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to >11.8 million confirmed cases with >545000 deaths worldwide by July 9, 2020 Patients with preexisting cardiovascular conditions are particularly at risk and have poor prognosis data suggest that cardiac injury, manifested by cardiac biomarker elevation, is detected in a sizable of COVID-19 patients and is associated with adverse outcomes and increased mortality. However, how useful cardiac biomarkers are in COVID-19 prognosis and how to utilize these markers have not been well defined The study will include all moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. The primary outcome is the relation between cardiac markers and mortality rate in critically ill COVID 19 patients The secondary outcome is the relationship between cardiac and inflammatory and coagulation markers

• Study Type: Observational
• Enrollment (Actual): 207

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt, 69711
    • Ain shams university

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

all moderate to severe COVID 19 patients who were admitted to ICU

Description

Inclusion Criteria:

• all moderate to severe COVID 19 patients who were admitted to ICU.
• Both genders
• age group 18-60 years

Exclusion Criteria:

• a refusal to participate in the study,
• pregnant patients,
• patients aged <18 or >60. years,
• recent history of acute myocardial infarction (< 1 month before admission).

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
moderate to severe COVID 19 patients; moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed	Other: laboratory investigation; observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
relation between cardiac markers and mortality rate in critically ill COVID 19 patients	relate cardiac biomarkers to mortality rate	4 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
relation ship between cardiac and inflammatory and coagulation markers	compare cardiac markers to inflammatory and coagulation laboratory findings	4 month

Collaborators and Investigators

• Sponsor: Ain Shams University
• Investigators: Study Chair: Fathy Tash, MD, Ain shams university

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2021
• Primary Completion (Actual): July 30, 2023
• Study Completion (Actual): July 30, 2023

Study Registration Dates

• First Submitted: September 9, 2021
• First Submitted That Met QC Criteria: September 9, 2021
• First Posted (Actual): September 10, 2021

Study Record Updates

• Last Update Posted (Actual): October 8, 2024
• Last Update Submitted That Met QC Criteria: October 7, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases
• Other Study ID Numbers: FMASU R 150 / 2021

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No